Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment
Department of Medicine, Division of Preventive and Behavioral Medicine
Adult; Behavior Therapy; Combined Modality Therapy; Double-Blind Method; Female; Fluoxetine; Humans; Male; Serotonin Uptake Inhibitors; Smoking; *Smoking Cessation
Life Sciences | Medicine and Health Sciences | Women's Studies
The authors evaluated the efficacy of fluoxetine hydrochloride (Prozac; Eli Lilly and Company, Indianapolis, IN) as an adjunct to behavioral treatment for smoking cessation. Sixteen sites randomized 989 smokers to 3 dose conditions: 10 weeks of placebo, 30 mg, or 60 mg fluoxetine per day. Smokers received 9 sessions of individualized cognitive-behavioral therapy, and biologically verified 7-day self-reported abstinence follow-ups were conducted at 1, 3, and 6 months posttreatment. Analyses assuming missing data counted as smoking observed no treatment difference in outcomes. Pattern-mixture analysis that estimates treatment effects in the presence of missing data observed enhanced quit rates associated with both the 60-mg and 30-mg doses. Results support a modest, short-term effect of fluoxetine on smoking cessation and consideration of alternative models for handling missing data.
Rights and Permissions
Citation: J Consult Clin Psychol. 2002 Aug;70(4):887-96.
Niaura, Raymond; Spring, Bonnie; Borrelli, Belinda; Hedeker, Donald; Goldstein, Michael G.; Keuthen, Nancy J.; DePue, Judy; Kristeller, Jean L.; Ockene, Judith K.; Prochazka, Allan; Chiles, John A.; and Abrams, David B., "Multicenter trial of fluoxetine as an adjunct to behavioral smoking cessation treatment" (2002). Women’s Health Research Faculty Publications. 402.